R&D
Basic Policy for R&D
Chugai’s mission is to generate a steady stream of innovative products to address unmet medical needs*1 and benefit the medical community and human health around the world. Based on this principle, we aim to create new drugs with first-in-class*2 or best-in-class*3 potential.
In allocating research resources, we prioritize projects based on the following criteria:
- The compound’s potential for development as a novel medicine that can be clearly differentiated
- Whether it has a scientific basis for addressing unmet medical needs
- Whether it is a project that will enable personalized healthcare (PHC)
At various decision points during research, we pursue drug discovery from the patient’s perspective in order to create medicines truly needed by patients and healthcare providers.
- *1 Medical needs that is not adequately met due to a lack of effective treatments
- *2 An original drug that is highly novel and useful, and will significantly change the therapeutic system
- *3 A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target
R&D Structure
-
- R&D Process
- It takes a long time to deliver medicines to patients. This section presents the process of developing new drugs.
-
- Research Structure and Network
- Chugai’s research division has strengths that other companies cannot possess, such as the benefits of collaboration with Roche and open innovation through industry-university collaboration.
-
- R&D Bases
- Introducing three domestic laboratories that serve as the core sites of Chugai Pharmaceutical and satellite laboratories in Japan and overseas.
Strategy and Technology
-
- Features of Drug Discovery Approaches
- Chugai develops its own innovative drug discovery technologies based on the “technology-driven approach”.
-
- Platforms & Technologies
- Chugai’s unique drug discovery technologies that satisfy unmet medical needs, including antibody engineering technologies, which are our strengths, as well as innovations in drug discovery processes that utilize AI.
-
- Clinical Development
- Under a lifecycle management system for project-level, we are striving to realize clinical trials distinguished by exceptional speed, efficiency and scientific rigor using digital technology.
-
- Production Technology
- Production efficiency by maintaining and strengthening the supply chain and evolving pharmaceutical functions through digital transformation (DX)
-
- Intellectual Property
- Strategy and features of Chugai’s global intellectual property strategy and patent portfolio.
